

Present:

Mr C Booth	Airedale NHS Trust
Dr M Crawford	
Ms P Daynes	Calderdale and Huddersfield NHS Foundation Trust
Ms J Swire	
Ms T Feber	Harrogate and District NHS Foundation Trust
Mrs C Hedges	
Ms R Hollis	Leeds Teaching Hospitals NHS Trust
Dr D Jackson (Chair)	
Ms K Norton	Mid Yorkshire Hospitals NHS Trust
Mr J Hancock	NHS North Yorkshire and York
Dr A Seymour	Wakefield Hospice
Mr M Harvey	York Hospitals NHS Foundation Trust
Ms M Jobling	
Dr L Munro	
Mr D Thomson	Yorkshire Cancer Network
Mrs J Toovey	
Mrs L White	

Apologies

Ms M Allinson, Mr D Fox, Mr I Hammond, S Keir, Dr S Kite, Ms J Mansell, Dr R Markham, Mrs C Rock

2. Action Log from the last meeting			
Log No	Action	Lead(s)	Deadline
71	The Action Log of the last meeting was agreed as an accurate record.	N/A	N/A
4. NCAG Action Plan			
Log No	Action	Lead(s)	Deadline
73	<p>Representatives gave an update on their Trusts position in relation to the YCN NCAG Action Plan.</p> <p>Commissioners are being encouraged to proactively engage with the gap analysis and local trust work plan's.</p> <p>It was agreed that a discussion regarding partnership working and a review of the model for chemotherapy services across the YCN needs to take place.</p> <p>To arrange a meeting with J Toovey, D Jackson, J Hancock and D Thomson to discuss this further.</p>	L White	03/03/2010

5. Guidelines			
Log No	Action	Lead(s)	Deadline
72	<p>The YCN Infection group are working on a YCN agreement for the management of neutropenic sepsis.</p> <p>In addition it was proposed that each trust sends their policy on neutropenic sepsis to L White. The network will then sign off each Trusts policy via the YCN Infection Group.</p> <p>To send L White your Trusts policy for neutropenic sepsis.</p>	All	10/03/2010
5.1 Extravasation			
Log No	Action	Lead(s)	Deadline
74	<p>D Thomson confirmed that the LTHT pharmacy colleagues are currently working on the revision of the Extravasation guidelines. Discussion on whether to include Topotarget in the guidelines is ongoing.</p> <p>Due to the delay D Thomson agreed to do a quick update of the guidelines prior to the big update.</p> <p>David Thomson to amend the policy and table at the next meeting.</p>	D Thomson	11/03/2010
5.2 CVC			
Log No	Action	Lead(s)	Deadline
75	<p>The CVC guidelines are currently being edited. These will then be sent to the Haematology Nurses for comments prior to wider consultation.</p> <p>To send L White the final edited version for circulation to the Haematology Nurses.</p>	Lead Chemotherapy Nurses	11/02/2010
5.3 Administration			
Log No	Action	Lead(s)	Deadline
76	<p>The chemotherapy administration guidelines need formatting prior to circulation for comments.</p> <p>To send the edited version of the Administration guidelines to L White for formatting and sending out for wider consultation.</p>	T Feber	11/02/2010
5.4 Anaphylaxis			
Log No	Action	Lead(s)	Deadline
77	<p>D Thomson has received all the Trusts policies for Anaphylaxis with exception to LTHT.</p> <p>D Thomson to contact L Prey for the LTHT policy.</p>	D Thomson	11/02/2010

6. Acute Oncology			
Log No	Action	Lead(s)	Deadline
78	<p>D Jackson and D Thomson gave feedback from the acute oncology half day meeting that was held on 28th January 2010.</p> <p>The two key areas to be addressed were the management of complications of anti cancer treatment and the early diagnosis of patients presenting acutely with symptoms relating to suspected cancer.</p> <p>The role of the nurse within acute oncology will be discussed further at the Chemotherapy Lead Nurses meeting.</p> <p>It is proposed that acute oncology meetings will be held every 3-4 months.</p> <p>L White to arrange a de-brief meeting with S Duffy, J Hancock, D Thomson, D Jackson and J Toovey to develop a work plan.</p>	L White	11/03/2010
7. Capacity			
Log No	Action	Lead(s)	Deadline
79	<p>D Thomson reminded colleagues that since the national tool had been trialled in Harrogate a new version has been launched (version 4).</p> <p>Leicester is currently trialling version 4 and the YCN is awaiting feedback before they proceed to pilot this version.</p> <p>To keep members updated on capacity planning.</p>	D Thomson	Ongoing
8. YCN NCAG Dataset			
Log No	Action	Lead(s)	Deadline
80	<p>D Thomson and D Jackson summarised the comments that had been received during the consultation of the following documents;</p> <p>Medical assessment pre chemotherapy Consent form Treatment plan</p> <p>A discussion took place regarding the wording on the consent form. It was proposed that the Lead Chemotherapy Nurses discuss this further with representatives of the YCN User Partnership Group.</p> <p>As only two comments had been received it was agreed that this is circulated again for final comments prior to the nurses meeting taking place on 22nd March 2010.</p> <p>L White to circulate the forms for final comments by 20 March 2010.</p> <p>Comments will then be sent to Louise O'Prey prior to the Chemotherapy Nurses.</p>	L White	20/03/2010

9. YCN Regimen List			
Log No	Action	Lead(s)	Deadline
81	<p>D Thomson confirmed that the regimen list will be going live on the YCN website and asked L White to circulate the link with the Action log.</p> <p>D Thomson provided each trust with a lists of all the regimens and the policy for preventing regular use of regimens not on the list.</p> <p>D Thomson asked each trust representative to complete the tick form for the regimens their trusts give, ask the Chair of the local chemotherapy group to sign them off and return to D Thomson by 14th April 2010.</p> <p>Each Trust to return signed form to D Thomson.</p>	All	14/04/2010
10. YCN Gateway Group Update			
Log No	Action	Lead(s)	Deadline
82	<p>D Thomson gave an update on the YCN Gateway Group meeting that took place on Wednesday 27th January.</p> <p>The group agreed that Gefitinib (Iressa) is recommended for use in the Yorkshire Cancer Network for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK.</p> <p>After an in-depth discussion the Gateway group felt it was difficult to agree a recommendation for Herceptin beyond progression in metastatic breast cancer. They agreed to make a recommendation to allow current practice to continue and await an answer to this difficult issue from NICE.</p> <p>The group agreed that Everolimus (Afinitor) remains not recommended for use in the Yorkshire Cancer Network for the second-line treatment of patients with metastatic renal cell cancer who are intolerant of or whose disease has progressed despite any prior VEGF receptor tyrosine kinase inhibitor therapy following a review of updated health economics evidence.</p> <p>These recommendations were sent to the YCN Management Board on 3rd February.</p> <p>To keep members updated on the future of the YCN Gateway group.</p>	D Thomson	Ongoing

Date of Next Meeting(s)

Wednesday 28th April 2010 2:00pm
 St Gemma's Hospice, Moortown, Leeds, LS17 6QD

Wednesday 23rd June 2010 2:00pm
 Kingswood House Surgery, 14 Wetherby Road, Harrogate, HG2 7SA

Wednesday 25th August 2010 2:00pm
 St Gemma's Hospice, Moortown, Leeds, LS17 6QD

Wednesday 27th October 2010 2:00pm
 St Gemma's Hospice, Moortown, Leeds, LS17 6QD

Wednesday 22nd December 2010 2:00pm
 St Gemma's Hospice, Moortown, Leeds, LS17 6QD